REGISTERED NUMBER: 01837276

NAPP RESEARCH CENTRE LIMITED DIRECTOR'S REPORT AND FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2020



CONTENTS OF THE FINANCIAL STATEMENTS for the Year Ended 31 December 2020

	Page
Director's Report	1
Income Statement	2
Balance Sheet	3
Notes to the Financial Statements	4

DIRECTOR'S REPORT for the Year Ended 31 December 2020

The director presents his report with the financial statements of the company for the year ended 31 December 2020.

The company has not traded during the year to 31 December 2020.

DIRECTOR

Changes in directors holding office are as follows:

B G Lea - appointed 1 January 2020

This report has been prepared in accordance with the provisions of Part 15 of the Companies Act 2006 relating to small companies.

ON BEHALF OF THE BOARD:

Bryan	REALEGOSSA
Date:	21 December 2021

INCOME STATEMENT for the Year Ended 31 December 2020

	Notes	2020 £	2019 £
TURNOVER		=	
OPERATING PROFIT a		-	-
Tax on profit	3	-	
PROFIT FOR THE FINA	ANCIAL YEAR	<u>-</u>	-

The notes form part of these financial statements

NAPP RESEARCH CENTRE LIMITED (REGISTERED NUMBER: 01837276)

BALANCE SHEET 31 December 2020

CURRENT ASSETS	Notes	2020 £	2019 £
Debtors	4	2,005,000	2,005,000
TOTAL ASSETS LESS CUP LIABILITIES	RRENT	2,005,000	2,005,000
CAPITAL AND RESERVES Called up share capital Retained earnings	5 6	1,000 2,004,000	1,000 _2,004,000
SHAREHOLDERS' FUNDS		2,005,000	2,005,000

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2020.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2020 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for:

- (a) ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
- (b) preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared in accordance with the provisions of Part 15 of the Companies Act 2006 relating to small companies.

The financial statements were approved by the director on ______21 December 2021 _____ and were signed by:

Bryan lea 10747478AE4044A...

B G Lea - Director

The notes form part of these financial statements

NOTES TO THE FINANCIAL STATEMENTS for the Year Ended 31 December 2020

1. ACCOUNTING POLICIES

Basis of preparing the financial statements

These financial statements have been prepared in accordance with the provisions of Section 1A "Small Entities" of Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

2. OPERATING PROFIT

As the company did not trade during the year, it has made neither a profit nor a loss.

3. TAXATION

Analysis of tax charge

No liability to UK corporation tax arose on ordinary activities for the year ended 31 December 2020 nor for the year ended 31 December 2019.

4. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2020	2019
	£	£
Other debtors	2,005,000	2,005,000

5. CALLED UP SHARE CAPITAL

All Maria San Carlo and Carlo and Carlo

Allotted, iss	sued and fully paid:	•			•
Number:	Class:		Nominal	2020	2019
		÷.	value:	£	£
1,000	Ordinary shares		£1	1,000	1,000

6. RESERVES

	Retained earnings £
At 1 January 2020 Profit for the year	2,004,000
At 31 December 2020	2,004,000

NOTES TO THE FINANCIAL STATEMENTS - continued for the Year Ended 31 December 2020

7. RELATED PARTY DISCLOSURES

The ultimate parent company of the group of undertakings for which group accounts are drawn up and of which the company is a member is Napp Pharmaceutical Holdings Limited.

Copies of the accounts of Napp Pharmaceutical Holdings Limited may be obtained from Cambridge Science Park, Milton road, Cambridge, CB4 0AB.

The ultimate controlling parties identified by the company are various trusts, which are ultimately held for the benefit of the families of the late Mortimer D. Sackler, M.D. and Raymond R. Sackler, M.D.